Serum factors and clinical characteristics associated with serum E-screen activity.
Serum factors and clinical characteristics associated with serum E-screen activity.
复制标题
血清因子和临床特征与血清电子屏幕活性相关。
DOI：
10.1158/1055-9965.epi-12-1117
复制
发表时间：
2013-05
期刊：
影响因子：
--
通讯作者：
Sprague BL
中科院分区：
文献类型：
--
作者：
Wang J;Trentham-Dietz A;Hemming JD;Hedman CJ;Sprague BL
E-Screen生物测定法可以测量人血清的促有丝分裂性，因此可以用作乳腺癌流行病学研究中的生物标志物。虽然已知检测的MCF-7细胞会响应雌激素而增殖，但对人血清样品中E-Screen活性变化的特定决定因素知之甚少。我们试图确定血清分子和患者的特点与血清E-筛选活动的绝经后妇女。年龄在55-70岁之间、无绝经后激素使用史或乳腺癌史的绝经后女性（N=219）完成问卷调查并提供血样。分析血清的E-Screen活性和各种分子，包括性激素、生长因子和环境化学物质。使用逐步选择程序来鉴定E-Screen活性的相关性。所有女性的血清样本均具有可检测的E-Screen活性，雌二醇当量中值为0.027 ng/mL，四分位数范围为0.018-0.036 ng/mL。在最终的多变量校正模型中，血清E-Screen活性与血清雌二醇、雌酮、IGFBP-3和睾酮水平（p<0.05）以及体重指数（p=0.03）正相关。血清E-Screen活性在SHBG（p<0.0001）和孕酮水平（p=0.03）较高的女性中较低。血清E-Screen活性根据内源性雌激素和其他血清分子的水平而变化。肥胖似乎赋予额外的血清促有丝分裂超出其对测量的激素和生长因子的影响。通过捕获由于各种患者和血清因素引起的促有丝分裂性，E-Screen可提供用作乳腺癌研究中的生物标志物的优势。
The E-Screen bioassay can measure the mitogenicity of human serum and thus may be useful as a biomarker in epidemiologic studies of breast cancer. While the assay’s MCF-7 cells are known to proliferate in response to estrogen, the specific determinants of variation in E-Screen activity in human serum samples are poorly understood. We sought to identify serum molecules and patient characteristics associated with serum E-Screen activity among postmenopausal women. Postmenopausal women (N=219) aged 55–70 with no history of postmenopausal hormone use or breast cancer completed a questionnaire and provided a blood sample. Serum was analyzed for E-Screen activity and a variety of molecules including sex hormones, growth factors, and environmental chemicals. Stepwise selection procedures were used to identify correlates of E-Screen activity. Serum samples from all women had detectable E-Screen activity, with a median estradiol equivalents value of 0.027 ng/mL and interquartile range of 0.018–0.036 ng/mL. In the final multivariable-adjusted model, serum E-Screen activity was positively associated with serum estradiol, estrone, IGFBP-3, and testosterone levels (p<0.05), as well as body mass index (p=0.03). Serum E-Screen activity was lower among women with higher SHBG (p<0.0001) and progesterone levels (p=0.03). Serum E-Screen activity varies according to levels of endogenous estrogens and other serum molecules. Obesity appears to confer additional serum mitogenicity beyond its impact on the measured hormones and growth factors. By capturing mitogenicity due to a variety of patient and serum factors, the E-Screen may provide advantages for use as a biomarker in breast cancer studies.